14700-62-0

Usage

Uses

Used in Pharmaceutical Industry:
NSC46839 is used as an antitumor agent for its ability to inhibit the growth of various cancer cell lines, including those of the breast, colon, and lung. Its anti-inflammatory and antioxidant properties contribute to its potential as a therapeutic agent in cancer treatment.
Used in Cancer Research:
NSC46839 is used as a research tool to investigate its mechanisms of action, including its effects on immune modulation and the promotion of apoptosis in cancer cells, which could lead to the development of novel cancer therapies.
Used in Drug Development:
NSC46839 is utilized in the development of new drugs targeting cancer treatment, with ongoing research aimed at understanding its full potential and optimizing its therapeutic applications.

InChI:InChI=1/C10H10N2/c1-2-4-9(5-3-1)8-10-11-6-7-12-10/h1-7H,8H2,(H,11,12)

Upstream product

• 59-98-3 tolazoline 
• 76100-32-8 2-Benzylimidazol-4,5-dicarbonsaeure 
• 140-29-4 phenylacetonitrile 
• 542-69-8 1-iodo-butane 
• 23230-39-9 1-[(dimethylamino)methyl]-imidazole 
• 122-78-1 phenylacetaldehyde 

Downstream Products

• 92506-23-5 2-benzyl-1-methyl-1H-imidazole 
• 38353-02-5 2-benzoylimidazole 
• 167758-82-9 4-(2-benzyl-1H-imidazol-1-yl)benzyl alcohol 
• 84694-93-9 1H-5-Acetyl-2-benzylimidazole 
• 162750-00-7 methyl 2-(phenylmethyl)-1H-imidazole-1-acetate 
• 1057137-21-9 2-Benzyl-1-[2-(3-nitrophenoxy)ethyl]-1H-imidazole 
• 122430-51-7 (4,5-dibromo-1H-imidazol-2-yl)-phenyl ketone 
• 84694-87-1 1-Acetyl-2-benzylimidazole 

Relevant academic research and scientific papers

Optimisation of imidazole compounds as selective TAAR1 agonists: Discovery of RO5073012

A series of imidazole compounds has been identified which affords potent and selective partial and full agonists of the TAAR1 receptor. Starting from 2-benzyl-imidazoline screening hits, a series of structurally related 2-benzyl- and 4-benzyl-imidazoles was investigated first, but it proved highly challenging to obtain compounds having sufficient selectivity against the adrenergic alpha 2 receptor. This issue could be successfully addressed by modification of the linker region and SAR exploration led to the discovery of highly selective isopropyl-substituted 4-aminomethyl-imidazole compounds. The work culminated in the identification of the selective TAAR1 partial agonist RO5073012 (4-chlorophenyl)-(1H-imidazol-4-ylmethyl)-isopropyl-amine, 24), which has a good pharmacokinetic profile after oral administration in rodents. RO5073012 has been found to be active in a behavioural rat model which is considered indicative for schizophrenia.

A convenient procedure for preparing hetarylamides and their analogs by dehydrogenation of the corresponding imidazoles

Conditions of aromatization of 2-(2-hetaryl)imidazolines and their analogs with various dehydrogenating agents were examined. A new catalytic system, Pd/C-diphenyl oxide, was studied, and the optimal catalyst:imidazoline ratio ensuring formation of 2-substituted imidazoles in high yield was found.

An efficient preparation of 2-imidazolines and imidazoles from aldehydes with molecular iodine and (diacetoxyiodo)benzene

2-Imidazolines were easily prepared in quite good yields from the reaction of aldehydes and ethylenediamine with molecular iodine in the presence of potassium carbonate. Moreover, 2-imidazolines obtained were smoothly oxidized to the corresponding imidazoles in good yields using (diacetoxyiodo)benzene at room temperature. Georg Thieme Verlag Stuttgart.

Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists

The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.

Expedient synthesis of substituted imidazoles from nitriles

Expedient and practical new methodology for the synthesis of substituted imidazoles was developed to provide a rapid access to a variety of 2-substituted, 1,2-disubstituted and 1,2,4-trisubstituted imidazoles by the direct CuCl-mediated reaction of nitriles with α-amino acetals in an intermolecular as well as intramolecular fashion.

A novel synthetic method for 2-arylmethyl substituted imidazolines and imidazoles from 2-aryl-1,1-dibromoethenes

Various 2-arylmethylimidazolines were prepared by treating readily available 2-aryl-1,1-dibromoethenes with ethylenediamine under mild conditions and further converted into the corresponding imidazoles smoothly with Swern oxidation. Graphical Abstract

New one-step synthesis of 2-aryl-1H-imidazoles: Dehydrogenation of 2-aryl-δ2-imidazolines with dimethylsulfoxide

A new one-step method for the preparation of 2-aryl-1Himidazoles 3, based on the DMSO dehydrogenation of 2-aryl-Δ2-imidazolines, is described. A comparative study between DMSO and 10% Pd/C, the best known catalyst employed in this transformation, has also been developed. Both protocols were carried out at 120 °C for 48 hours.

5-(1-(IMIDAZOL)METHYL)-3,3-DISUBSTITUTED-2(3H)FURANONE DERIVATIVES

Furanone compounds and compositions having anticholinergic activity are described. The compounds have the formula: STR1 wherein: the dashed line indicates either the 4,5-unsaturated or the 4,5-dihydrofuranone ring;R 1 and R 2 may be the same or different and are hydrogen, thienyl, furanyl, or cycloalkyl (C. sub.3-C 6), benzyl, phenyl, substituted phenyl or substituted benzyl wherein the phenyl or benzyl group may be substituted with halogen, trifluoromethyl, lower alkyl, lower alkoxy or hydroxy;R. sub.3, R 4 and R 5 may be the same or different and are hydrogen, lower alkyl, lower alkyl substituted with a halogen, alkoxy, amino or carboxylic acid group, an alkyl or alkylene bridge between R 4 and R. sub.5 or R 3 and the ring N, trifluoromethyl, nitro, a cycloalkyl group containing 3 to 6 carbons, halogen, benzyl, phenyl, substituted phenyl or substituted benzyl, for which the substituents are the same as those set forth for R 1 and R 2 substituted benzyl or phenyl.R 6 in the dihydrofuranone series is hydrogen or lower alkyl.Also described are the pharmaceutically acceptable quaternary alkyl and acid addition salts of such compounds. The compounds are particularly useful in the treatment of neurogenic bladder disorder and chronic obstructive pulmonary diseases.

Dehydrogenation of Imidazolines to Imidazoles with Pd-Carbon

A new and mild method for converting imidazoline derivatives to imidazole derivatives using Pd-C is described.The dehydrogenation of 2- and 2,4-disubstituted imidazolines is carried out in refluxing toluene using Pd-C in good yields.Mixed results are obtained with 4-substuted imidazolines.